Senator Bill Cassidy, R-Louisiana, is working with Democratic colleagues Michael Bennet of Colorado and Maggie Hassan of New Hampshire to introduce a bill this month to stop patients from getting surprise medical bills; the FDA warned a major Canadian drug distributor, CanaRx to stop selling unapproved and mislabeled medicines to Americans looking to save money on prescriptions; Democratic leaders in the House of Representatives are trying to keep the chamber united behind narrower proposals aimed at strengthening the Affordable Care Act and lowering drug prices in the wake of the introduction of a Medicare for All bill.
Senator Bill Cassidy, R-Louisiana, is working with Democratic colleagues Michael Bennet of Colorado and Maggie Hassan of New Hampshire to introduce a bill this month to stop patients from getting surprise medical bills, The Hill reported. Lawmakers are pushing to prevent examples like that of a Texas teacher whose story went viral last year after he got a $108,951 bill from the hospital after his heart attack because the facility was not in his insurance network.The FDA warned a major Canadian drug distributor, CanaRx to selling unapproved and mislabeled medicines to Americans looking to save money on prescriptions, The New York Times reported. CanaRx sells prescription medicines at a lower cost to hundreds of public and private employer programs in the United States.Democratic leaders in the House of Representatives are trying to keep the chamber united behind narrower proposals aimed at strengthening the Affordable Care Act and lowering drug prices in the wake of the introduction of a Medicare for All bill, which has energized the party’s progressive base. Top Democrats are trying to avoid criticizing the bill publicly, even as they express little enthusiasm, Politico reported.
Race/Ethnicity May Influence Local Recurrence in DCIS, Adjuvant Treatment
December 6th 2023Disparities in 10-year local recurrence following breast-conserving surgery were seen among women with ductal carcinoma in situ (DCIS) treated over a nearly 4-decade span at Memorial Sloan Kettering Cancer Center, with Black women having the highest rate.
Read More
Study: SGLT2is Should Be Continued Despite Initial eGFR Decline in Patients With HFmrEF/HFpEF
December 6th 2023Despite an initial drop in estimated glomerular filtration rate (eGFR) after 1 month of dapagliflozin, researchers say this is not associated with subsequent risk of cardiovascular or kidney events for patients with heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF).
Read More